1932

Abstract

Reversible protein acetylation provides a central mechanism for controlling gene expression and cellular signaling events. Two pharmacological inhibitors of protein deacetylation are currently approved for the treatment of human cancer, and numerous follow-on compounds are in clinical development for oncology and non-oncology indications. The inhibitors target members of a family of enzymes known as histone deacetylases (HDACs). Surprisingly, HDAC inhibitors have also been shown to be efficacious in preclinical models of heart failure. This review highlights roles of HDACs in the heart and the therapeutic potential of HDAC inhibitors for the treatment of heart failure.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-pharmtox-010611-134712
2012-02-10
2024-03-29
Loading full text...

Full text loading...

/content/journals/10.1146/annurev-pharmtox-010611-134712
Loading
/content/journals/10.1146/annurev-pharmtox-010611-134712
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error